Axela teams with John Hopkins for cardiac research
Researchers from Johns Hopkins University School of Medicine have entered into an agreement with Axela to use dotLab technology in a clinical trial that directly evaluates circulating cardiac troponin (cTn) complexes.

Jennifer Van Eyk, MD, director of the Johns Hopkins NHLBI Proteomics Center in Baltimore, is the lead researcher for the trial, which will look at the prognostic value of troponin complexes, as well as post translational modifications to cardiac troponin I (cTnI) in patients with acute MI.

The novel dotLab assay can directly detect circulating cTnI bound to cTnC and cTnT in the serum of patients with acute MI, according to the Toronto-based Axela. The assay is also able to probe the integrity of cTnI and determine if the protein is degraded by looking for the presence of specific epitopes, the company said.